NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $0.86 -0.01 (-1.42%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.86 +0.00 (+0.14%) As of 05/22/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Heron Therapeutics Stock (NASDAQ:HRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Heron Therapeutics alerts:Sign Up Key Stats Today's Range$0.85▼$0.9050-Day Range$0.75▼$1.3152-Week Range$0.74▼$2.30Volume1.05 million shsAverage Volume2.68 million shsMarket Capitalization$162.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids. Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S. Food and Drug Administration approval in 2016 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. The company also advanced HTX-019, an injectable emulsion formulation of aprepitant, which obtained FDA approval as the first non-polyethylene glycol formulation for acute CINV prophylaxis in adults. The company’s most advanced pipeline candidate is HTX-011, an investigational, long-acting, non-opioid local anesthetic that combines bupivacaine and low-dose meloxicam. HTX-011 is designed to provide extended post-operative analgesia and has been evaluated in Phase III trials across multiple surgical settings. In addition to HTX-011, Heron is developing other drug candidates to address various analgesic and supportive care needs and is exploring strategic collaborations to broaden the commercial reach of its portfolio. Founded in 2011 and headquartered in Redwood City, California, Heron Therapeutics completed its initial public offering in 2015 and is listed on Nasdaq under the ticker HRTX. The company primarily serves the U.S. market and is pursuing global partnerships to expand its geographic footprint. Heron’s leadership team comprises industry veterans with expertise in clinical development, regulatory affairs and commercialization, supporting the company’s mission to deliver innovative treatments that enhance patient care.AI Generated. May Contain Errors. Read More Heron Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreHRTX MarketRank™: Heron Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 535th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingHeron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialHeron Therapeutics has a consensus price target of $4.50, representing about 424.0% upside from its current price of $0.86.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.05) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 21.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Heron Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.02% of the float of Heron Therapeutics has been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 0.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News SentimentN/A News SentimentHeron Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows10 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.86% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRTX Stock News HeadlinesHeron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Rating of "Hold" by AnalystsMay 23 at 4:15 AM | americanbankingnews.comHeron Therapeutics (NASDAQ:HRTX) Downgraded to Sell Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comWhere did Vanguard quietly put $101 billion?Vanguard holds $101 billion in three AI companies most investors have never heard of. BlackRock holds $82 billion. State Street, $47 billion - and that's before counting Geode, Morgan Stanley, JPMorgan, and T. Rowe Price. Analyst George Gilder, who spotted the iPhone a decade early, calls them the 'Trillion Dollar Triangle' - chips he says could do in minutes what today's AI data centers do in hours, using up to 90% less energy. He believes the window to get positioned before the broader market catches on may already be closing.May 24 at 1:00 AM | Eagle Publishing (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)May 14, 2026 | theglobeandmail.comHeron Therapeutics (HRTX) price target decreased by 15.38% to 3.74May 14, 2026 | msn.comHeron (HRTX) Q1 2026 Earnings Call TranscriptMay 12, 2026 | finance.yahoo.comAcute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales DeclineMay 11, 2026 | finance.yahoo.comHeron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call TranscriptMay 11, 2026 | seekingalpha.comSee More Headlines HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.30 at the beginning of the year. Since then, HRTX stock has decreased by 33.9% and is now trading at $0.8588. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The biotechnology company earned $34.71 million during the quarter, compared to analysts' expectations of $36.72 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 7,747.30% and a negative net margin of 20.53%. Read the conference call transcript. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiaries of Heron Therapeutics: Heron Therapeutics B.V.. Who are Heron Therapeutics' major shareholders? Top institutional investors of Heron Therapeutics include Orbimed Advisors LLC (5.19%), Pale Fire Capital SE (1.44%), Renaissance Technologies LLC (0.91%) and Bank of New York Mellon Corp (0.22%). Insiders that own company stock include Rubric Capital Management Lp, Adam Morgan, Craig A Collard, Ira Duarte and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/11/2026Today5/24/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 3 days ago, HRTX's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRTX CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees300Year Founded1983Price Target and Rating Average Price Target for Heron Therapeutics$4.50 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+424.0%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.19 million Net Margins-20.53% Pretax Margin-20.53% Return on Equity-7,747.30% Return on Assets-8.94% Debt Debt-to-Equity Ratio17.51 Current Ratio2.53 Quick Ratio1.51 Sales & Book Value Annual Sales$154.90 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book21.47Miscellaneous Outstanding Shares189,280,000Free Float178,187,000Market Cap$162.55 million OptionableOptionable Beta1.70 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:HRTX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredYou have until June 1Macroeconomic strategist Dr. Mark Skousen believes June 1 marks a critical turning point for one of the most o...The Oxford Club | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
